Daewoong pharmaceutical (069620) Fundamentals 2026 — P/E 6.9x, Revenue Analysis | SniperIQ
Daewoong pharmaceutical (069620) is a KR-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ₩1.38T, trading at ₩119700.00 on the KSC. This SniperIQ fundamentals page covers Daewoong pharmaceutical's valuation (P/E 6.9x, P/B 1.4x), profitability (net margin 12.6%), revenue (₩1.57T in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Daewoong pharmaceutical's market cap?
Daewoong pharmaceutical (069620) has a market capitalization of approximately ₩1.38T, trading at ₩119700.00 on the KSC. Market cap moves with the live share price.
What is Daewoong pharmaceutical's P/E ratio?
Daewoong pharmaceutical's trailing twelve-month P/E ratio is 6.9x, with a price-to-book (P/B) of 1.4x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Daewoong pharmaceutical?
Daewoong pharmaceutical runs a net profit margin of 12.6%, a gross margin of 51.4%, and an operating margin of 11.3%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Daewoong pharmaceutical generate?
Daewoong pharmaceutical reported revenue of ₩1.57T for fiscal year 2025, with net income of ₩195.9B and earnings per share (EPS) of 17021. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Daewoong pharmaceutical pay a dividend?
Daewoong pharmaceutical offers a trailing dividend yield of about 0.5%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Daewoong pharmaceutical financially healthy?
Daewoong pharmaceutical carries a debt-to-equity ratio of 0.88x and a current ratio of 1.12x, with a market beta of 0.01. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Daewoong pharmaceutical a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Daewoong pharmaceutical (069620) the key facts are: market cap ₩1.38T, P/E 6.9x, revenue ₩1.57T, 52-week range 105000-199400. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Daewoong pharmaceutical's full fundamentals live
Get Daewoong pharmaceutical's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.